As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
Jonathan Andrus, co-CEO of CRIO, discusses how increased reliance on site-based technologies and eSource is strengthening ...
In today’s ACT Brief, we examine how fragmented data collection continues to challenge trial quality, how hybrid outsourcing ...
Jonathan Andrus, co-CEO of CRIO, explains how protocol-driven eSource templates and standardized data capture are improving consistency, oversight, and efficiency across clinical trial sites.
In today’s ACT Brief, we explore how sites are taking the lead on AI adoption to strengthen feasibility and enrollment, why earlier cross-functional alignment is critical in data-driven trials, and ...
Andrus: The biggest risk is fragmented, disconnected data collection across sites. If you think about a large phase 3 trial ...
In today’s ACT Brief, we examine how protocol-driven eSource is reshaping data capture at sites, how digital protocols and ...
In today’s ACT Brief, we examine how site-level data capture is becoming central to trial execution, how Merck and Mayo ...
Mayo Clinic, for its part, described the collaboration as its first strategic partnership of this scale with a global ...
Angela Zubel, chief development officer, Debiopharm, discusses why 2026 marks a shift from AI pilots to broader operational ...
Angela Zubel, chief development officer, Debiopharm, explains how AI-enabled site selection, patient allocation, and real-time data monitoring can reduce costs, shorten timelines, and limit ...
As clinical development grows more complex, sponsors are rethinking how outsourcing models, technology, and partnerships align to support both speed and sustainability. The shift toward hybrid models, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results